Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer.
Authors : Aiello MM, Solinas C, Santoni M, Battelli N, Restuccia N, Latteri F, Paratore S, Verderame F, Albanese GV, Bruzzi P, Soto Parra HJ Year : 2020 Journal : Front Oncol
Radiomics and radi-…omics" in cancer immunotherapy: a guide for clinicians."
Authors : Porcu M, Solinas C, Mannelli L, Micheletti G, Lambertini M, Willard-Gallo K, Neri E, Flanders AE, Saba L Year : 2020 Journal : Crit Rev Oncol Hematol
Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
Authors : De Silva P, Aiello M, Gu-Trantien C, Migliori E, Willard-Gallo K, Solinas C Year : 2020 Journal : Int J Cancer
Programmed Cell Death-Ligand 2: A Neglected But Important Target in the Immune Response to Cancer?
Authors : Solinas C, Aiello M, Rozali E, Lambertini M, Willard-Gallo K, Migliori E Year : 2020 Journal : Transl Oncol
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Authors : Solinas C, Gu-Trantien C, Willard-Gallo K Year : 2020 Journal : ESMO Open